article thumbnail

Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more

GeekWire

Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies , the company said today in a regulatory filing. ” Adams was previously managing director of healthcare advanced analytics at SVB Securities and was a principal at Booz Allen Hamilton. . Mark Adams.

article thumbnail

Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies

GeekWire

Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. The company said it was shutting a program focused on heart failure and outlined reset priorities for other programs. million in cash, cash equivalents, and marketable securities on hand.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Adaptive Biotechnologies lays off about 100 people, 12% of headcount, to ‘streamline our workforce’

GeekWire

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We

article thumbnail

Tech Moves: F5 adds CTO and HR chief; Adaptive names CFO; Techstars Seattle leaders depart

GeekWire

F5 Photos) — Seattle-based application security and delivery giant F5 announced two new executive appointments this week: Lyra Schramm , the company’s new chief people officer, and Kunal Anand , chief technology officer. Techstars announced one month later that it was shutting down the Seattle program. Sarah Studer.

article thumbnail

Vancouver, Wash. biotech company Absci files to go public

GeekWire

Securities and Exchange Commission. The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. 2020 revenue was $4.7 million, up from $2 million for 2019.

Company 122
article thumbnail

Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public

GeekWire

Securities and Exchange Commission comes on the heels of two rounds of private funding already this year tallying $140 million, including a $60 million Series B round in May. In June, Seattle-based Nautilus Biotechnology, led by Isilon Systems co-founder Sujal Patel, went public via a SPAC merger. The Redmond, Wash. Via SEC filing).

article thumbnail

Biotech giant Moderna will open tech office in Seattle, plans to hire up to 220 workers

GeekWire

The news is a bright spot for Seattle’s biopharma scene which has seen employee cuts at several biotech companies recently as part of wider layoffs in the industry, including at NanoString Technologies , Sana Biotechnology , Eliem Therapeutics and Neoleukin Therapeutics. It reported $19.3 billion in revenue for 2022, up from $18.5